Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07220148

Multimodal Immune and Neuroendocrine Assessment in Drinkers

The goal of this clinical trial is to better understand how blood flow in the brain, levels of the hormone, cortisol, and levels of an immune factor, interleukin-6, change in response to pictures of alcohol versus water pictures of water in healthy people who regularly consume alcohol. Researchers will learn about how the brain processes our environment and how it relates to people's drinking behaviors. This information is important because it may allow us to develop new treatments for Alcohol Use Disorders.

Participants will be asked to fill out psychological questionnaires at the first appointment. Then, they will do MRI scans with blood draws at visits 2-6. After each MRI scan, participants will undergo the Alcohol Taste Test, which involves drinking beer.

There will be a total of 3 visits at baseline, 2 visits one year later, and 2 visits one year after that. Each visit will last 2 hours. Each year, participants will do 21 days of surveys on a smart phone (4 surveys a day; each survey takes less than 2 minutes). The total time commitment for the entire study will be 23 hours.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Alcohol Drinking Behavior Drinking Behavior

Age range

21 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Auburn University MRI Center

Auburn, Alabama, 36832, United States

Location contact

Tom Denney, PhD

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

In this study, researchers will recruit 234 individuals who report binge use of alcohol or who consume alcohol moderately with no episodes of binge drinking. All participants will be recruited from the community primarily through advertisements in local newspapers, online venues like craigslist, flyers, and list-serve emails, as well as through radio and other media advertisements.

Inclusion criteria

All Participants:

  • Male and Females between the ages of 21-25
  • able to read and write in English and complete study evaluations
  • able to provide negative breathalyzer and negative toxicology screenings for substances at all study appointments
  • able to provide written and verbal consent.
  • Must be a beer drinker (not exclusively), to ensure subjects are not averse to the taste of beverages presented in the ATT
  • BMI of 18-35

Binge Drinkers:

  • At least twice per month binge drinking and weekly alcohol use of at least 8 standard drinks/week females or 15 or more drinks for males for the past year, with binge drinking defined as drinking enough alcohol that brings blood alcohol concentration to 0.08 percent or higher in about 2 hours, which is typically equivalent to consuming 5 or more drinks for males, or 4 or more drinks for females.

Social Drinkers:

  • at least weekly alcohol use for the past 6 months not to exceed 7 standard drinks/wk for women and 14 standard drinks/week for males, with no episodes of binge drinking in the past year

Exclusion criteria

All Participants:

  • Any psychotic disorder or current psychiatric symptoms requiring specific attention, including active symptoms of psychosis or suicidal/homicidal ideation
  • meets criteria for current or past moderate or severe substance use disorder
  • women who are pregnant or lactating
  • inability to give informed consent
  • any contraindications for MRI (e.g., medical devices in the body, claustrophobia, etc)
  • current PTSD or acute stress disorder
  • other illicit drug use as determined by a urine drug screen

Treatment and study plan

Alcohol Cue Reactivity and Laboratory Alcohol Administration Paradigm

Behavioral

Mechanistic evaluation of neural, neuroendocrine, and immune biomarkers underlying alcohol cue reactivity and drinking behavior.

Primary outcomes

  1. Neural cue reactivity to alcohol stimuli (fMRI BOLD response)

    Time frame: Baseline, 1-year follow-up, 2-year follow-up.

    Change in blood-oxygen-level dependent (BOLD) activation to alcohol versus neutral cues in regions of interest (e.g., medial prefrontal cortex, posterior cingulate cortex, striatum) measured using 7 Tesla functional MRI.

  2. Cortisol and IL-6 reactivity to alcohol cues

    Time frame: Baseline, 1-year follow-up, 2-year follow-up.

    Change in plasma cortisol and interleukin-6 concentrations (pg/mL) from pre- to post-cue exposure in the laboratory alcohol administration session.

  3. Alcohol craving and consumption following cue exposure

    Time frame: Baseline, 1-year follow-up, 2-year follow-up.

    Alcohol craving ratings on the Alcohol Urge Questionnaire (1-7 visual analog scale, high scores mean worse outocme) and total volume of alcohol consumed (mL) during the Alcohol Taste Test following cue exposure.

Secondary outcomes

  1. Real-world craving and drinking behavior (EMA)

    Time frame: 30-day EMA period after each assessment wave (baseline, 1 year, 2 years).

    Ecological Momentary Assessment (EMA) measures of craving, alcohol use, and contextual factors collected via smartphone app 3-5 times daily for 30 days following each lab session.

  2. Composite biomarker index of neurobiological vulnerability

    Time frame: Baseline, 1-year follow-up, 2-year follow-up.

    Composite score derived from standardized z-scores across neural, neuroendocrine, and immune cue-reactivity measures representing multi-attribute vulnerability.

Study contacts

Contact information is provided by the study sponsor or research team.

Sara Blaine, PhD

CONTACT

[email protected]

6103041056

Sponsors and collaborators

Lead sponsor

Auburn University

Other

Registry information

Official study title

Multimodal Assessment of Neural, Neuroendocrine, and Immune Cue Responses in Binge Drinkers in the Laboratory and Real World

Acronym: MIND

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Oct 23, 2025
Registry last updated
Oct 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.